U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 3

1.
Figure 1

Figure 1. Consolidated Standards of Reporting Trials Study Flow Diagram. From: Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition.

FMP indicates final menstrual period; HT, hormone therapy; and VMS, vasomotor symptoms.

Nancy E. Avis, et al. JAMA Intern Med. ;175(4):531-539.
2.
Figure 2

Figure 2. Kaplan-Meier Estimates of Total VMS Duration of Frequent VMS by Menopausal Transition Stage at First VMS Report (A) and by Race/Ethnicity (B). From: Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition.

A, By menopausal transition stage at first VMS report. B, By race/ethnicity. VMS indicates vasomotor symptoms. Menopausal transition stage at first VMS report is missing for 9 participants. Median duration for each group is calculated as the value on the x-axis corresponding to the intersection of the dashed horizontal line (50%) with the group’s survival curve.

Nancy E. Avis, et al. JAMA Intern Med. ;175(4):531-539.
3.
Figure 3

Figure 3. Kaplan-Meier Estimates of Post-FMP Persistence of Frequent VMS by Menopausal Transition Stage at First VMS Report and by Race/Ethnicity. From: Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition.

A, By menopausal transition stage at first VMS report. B, By race/ethnicity. FMP indicates final menstrual period; VMS, vasomotor symptoms. Menopausal transition stage at first VMS report is missing for 2 participants. Median duration for each group is calculated as the value on the x-axis corresponding to the intersection of the dashed horizontal line (50%) with the group’s survival curve.

Nancy E. Avis, et al. JAMA Intern Med. ;175(4):531-539.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center